GlobeNewsWire
21 Jul 2026, 10:45 UTC · 5h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
BioNTech's pumitamig showed encouraging efficacy in non-small cell lung cancer patients during the ROSETTA Lung-02 trial. — Positive clinical data for a late-stage oncology asset is a primary driver of valuation for biotech companies.
+0.60BioNTech will report its second quarter 2026 financial results and provide a corporate update on August 4, 2026. — Earnings dates create known volatility events, though the announcement of the date itself is a routine administrative update.
+0.20BioNTech will present new clinical data and trial updates from its late-stage oncology pipeline at ASCO 2026. — Future data presentations at major conferences are catalysts that investors price in as potential inflection points.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Mentioned as a partner in a trial showing encouraging efficacy for non-small cell lung cancer.
The company is announcing upcoming financial results and reporting encouraging efficacy for a clinical trial.
Mentioned only as a collaborator in a general company description.
Mentioned only as a collaborator via Genentech in a general company description.
Mentioned only as a collaborator in a general company description.
[mutual] BioNTech has partnered with Bristol Myers Squibb on programs including the pumitamig bispecific antibody.
[mutual] BioNTech is identified as having a partnership with Pfizer to accelerate innovation.
[mutual] BioNTech has partnered with Genentech, which is a member of the Roche Group.
[mutual] BioNTech is identified as having a partnership with Genmab.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Zacks Investment Research
1h ago
